Featured Viewpoint on eCROs
The global biopharmaceutical industry faces a daunting array of challenges: intense competitive pressure to bring innovative compounds to market more quickly; rapidly rising development costs; a high rate of failure for pivotal clinical trials; and the exponential growth of study-related data to meet expanding regulatory requirements.
The evolving biopharmaceutical services market
Josef von Rickenbach, Chairman and CEO of PAREXEL International, founded the company in 1982, and has seen the biopharmaceutical services industry change dramatically over the intervening years. In a recent interview, he discussed the evolving relationship between biopharmaceutical companies and CROs, and how he thinks that relationship will change in the years ahead.
Best Practices: Five Key Levers
Faced with growing financial and competitive pressures, biopharmaceutical companies are seeking new ways to increase productivity in every phase of clinical development. While there are many ways to improve clinical trials, here are five proven “levers” that have helped many companies achieve cost and time efficiency improvements in clinical development through better access to comprehensive, integrated information, as well as enhance the alignment of expertise, processes, and technologies: